News
Healthcare Leadership Series: Interview with Brad Walsh
Click here to watch the interview with Brad Walsh, CEO of Minomic International Ltd. The interview is about: - The perspectives on leadership - Best aspects of being involved in the health sector - Important traits a leader should have in the sector - The biggest...
Minomic Signs Agreement with US Pathology Laboratory
Agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients Read Chinese version of the news "Minomic Signs Agreement with US Pathology Laboratory" here February 14, 2019: [Sydney] Minomic International Ltd is pleased to...
Minomic announces completion of demerger of GlyTherix Ltd
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd,...
Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch - offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize at the...
Minomic secures key patent in the United States and China
Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology company specializing in the...
Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
58% Fewer patients proceed to Biopsy. US Rollout well advanced. May 17, 2018: [Sydney] Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer...
ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial
A poster with headline results of the MiCheck-01 prospective trial was presented by Dr Brad Walsh, Minomic’s CEO at ASCO GU Cancers Symposium 2018 on 8 February. The 350-patient study highlights the test’s performance in differentiating aggressive from non-aggressive...
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...
Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access July 18, 2017: [Sydney] Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US...